Efficacy of propafenone in paramyotonia congenita

Neurology. 2007 Mar 27;68(13):1080-1. doi: 10.1212/01.wnl.0000257825.29703.e8.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Action Potentials / drug effects
  • Action Potentials / genetics
  • Adult
  • Anti-Arrhythmia Agents / administration & dosage
  • DNA Mutational Analysis
  • Drug Administration Schedule
  • Genetic Markers / genetics
  • Genetic Testing
  • Humans
  • Male
  • Muscle Hypertonia / drug therapy
  • Muscle Hypertonia / genetics
  • Muscle Hypertonia / physiopathology
  • Muscle, Skeletal / drug effects*
  • Muscle, Skeletal / metabolism
  • Muscle, Skeletal / physiopathology
  • Mutation / genetics
  • Myotonic Disorders / drug therapy*
  • Myotonic Disorders / genetics
  • Myotonic Disorders / physiopathology
  • NAV1.4 Voltage-Gated Sodium Channel
  • Paralysis / drug therapy
  • Paralysis / genetics
  • Paralysis / physiopathology
  • Propafenone / administration & dosage*
  • Sodium Channel Blockers / administration & dosage*
  • Sodium Channels / drug effects*
  • Sodium Channels / genetics
  • Sodium Channels / metabolism
  • Treatment Outcome

Substances

  • Anti-Arrhythmia Agents
  • Genetic Markers
  • NAV1.4 Voltage-Gated Sodium Channel
  • SCN4A protein, human
  • Sodium Channel Blockers
  • Sodium Channels
  • Propafenone